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Abstract
We have recently shown that brief episodes of hypothermic perfusion interspersed with periods of normothermic perfusion,
referred to as temperature preconditioning (TP), are cardioprotective and can be mimicked by consecutive isoproterenol/
adenosine treatment. Here we investigate the optimal temperature for TP and whether TP further enhances protection
provided by hypothermic ischemia with or without polarized cardioplegic arrest. Three experimental groups of
Langendorff-perfused rat hearts were used. In the ﬁrst group, hearts were subjected to three episodes of hypothermic
perfusion at 7, 17, 26 and 328C during the TP protocol, followed by 30 min normothermic index ischemia and 60 min
reperfusion (378C). Protein kinase A (PKA) activity and cyclic AMP (cAMP) concentrations were measured prior to index
ischemia. In the second group, TP (268C) hearts were subjected to two hours hypothermic index ischemia at 268C and two
hours normothermic reperfusion. In the third group, TP (268C) hearts or hearts treated with isoproterenol/adenosine
(pharmacological simulation of TP) were subjected to four hours hypothermic index ischemia with procaine-induced
polarized cardioplegia at 268C followed by two hours normothermic reperfusion. Hemodynamic function recovery, lactate
dehydrogenase release and infarct size were used to assess cardioprotection. TP at 268C resulted in highest
cardioprotection, increased cAMP concentration and PKA activity, while TP at 78C exacerbated ischemia/reperfusion
damage, and had no effect on cAMP concentration or PKA activity. TP at 268C also protected hearts during hypothermic
ischemia with or without polarized cardioplegia. Isoproterenol/adenosine treatment conferred additional protection similar
to TP. In conclusion, the study shows that TP-induced cardioprotection is temperature dependent and is optimal at 268C;
TP confers additional protection to hypothermia and polarized cardioplegia; and that the pharmacological treatment based
on the mechanism of TP (consecutive isoproterenol/adenosine treatment) is a potential cardioprotective strategy that can
be used during heart surgery and transplantation.
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Introduction
We have recently described a novel protocol for cardioprotec-
tion that involves subjecting the heart to brief, transient
hypothermic (268C) episodes prior to index ischemia.
1 The
choice of 268C was based on the data of Stowe et al.,
2 indicat-
ing that this is the lowest temperature that can be used
without impaired contractility. Such temperature precondi-
tioning (TP) is as least as good, if not better than ischemic pre-
conditioning (IP) in terms of hemodynamic function,
reduction in arrhythmias, oxidative stress and lactate dehy-
drogenase (LDH) release.
1 We have also shown that the sig-
naling pathway mediating TP involves activation of cyclic
AMP (cAMP)-dependent protein kinase A (PKA) followed
by activation of protein kinase C (PKC).
3 A modest increase
in reactive oxygen species has been found to play an
important role, and an involvement of AMP-activated
protein kinase (AMPK) cannot be excluded.
1 The cardiopro-
tective effects of TP, like IP, were associated with decreased
oxidative stress at the end of index ischemia and during
reperfusion which prevents opening of the mitochondria per-
meability transition pore (MPTP) leading to both improved
contractile function and decreased necrotic damage.
1,3
Hypothermia is routinely used in conjunction with cardi-
oplegic solutions to protect the heart during open heart
surgery. Hypothermia (25–278C) affords considerable pro-
tection against an expected ischemic insult in patients
undergoing cardiac surgery for coronary bypass grafting
or valve repair.
4 This protection is associated with better
tissue perfusion, improved metabolic and mechanical func-
tion, fewer arrhythmias and reduced infarct size upon
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5,6 Hypothermia may mediate its protection by
slowing ATP-dependent metabolism and hence mitochon-
drial respiration and oxidative phosphorylation.
7 However,
hypothermia also increases intracellular [Ca
2þ] ([Ca
2þ]i),
which may be harmful to the myocardium. Increased Ca
2þ
loading during hypothermia may derive from increased net
inward Ca
2þ current ﬂux due to markedly increased action
potential duration, slowing down Ca
2þ removal mediated
by ATP-dependent pumps of the sarcolemma and sarcoplas-
mic reticulum.
2 Hypothermia also diminishes Na
þ-pump
activity and increases Na
þ inﬂux via Na
þ/H
þ exchange
8
leading to increased [Na
þ]i.T h i sN a
þ accumulation results
in further increases in [Ca
2þ]i through inhibition or reversal
of the Na
þ/Ca
2þ exchanger.
2 Elevated [Ca
2þ]i can exert dele-
terious effects such as hypercontracture that may jeopardize a
full return of function on re-warming,
2 eventually leading to
circulatory collapse.
9 Whether the cardioprotective efﬁcacy of
TP can also extend to hypothermic ischemic arrest is not
presently known.
Along with hypothermia, cardioplegic arrest remains a
popular measure to diminish ischemia-induced myocardial
injury during cardiac surgery. Cardioplegic arrest during
index ischemia is usually induced by a hyperkalemic extra-
cellular solution that induces depolarization.
10 Despite its
almost universal usage, depolarized cardioplegic arrest
has serious disadvantages including Na
þ and Ca
2þ accumu-
lation in myocardium.
11 This can lead to myocardial and
microvascular injury, coronary vasoconstriction and
spasm,
12 arrhythmias,
13 right and left ventricular stunning,
and can potentiate the local inﬂammatory response.
14 An
alternative to depolarized arrest is to induce electromechani-
cal arrest in a polarized or hyperpolarized state. This will
retain ionic homeostasis during ischemia. Sodium channel
blockers such as tetrodotoxin, procaine or lidocaine are
able to induce a polarized arrest, considerably improving
heart preservation during cardiac surgery.
11
However, neither hypothermia nor polarized cardiople-
gia totally abolishes ischemia-induced myocardial damage.
Thus, additional protection is needed to improve heart
recovery following global ischemia in these conditions
occurring during cardiac surgery. This study was aimed
at determining whether TP or its pharmacological mimic
(consecutive isoproterenol/adenosine treatment
3) confer
additional protection to hypothermia and polarized cardio-
plegic arrest. Prior to this we also sought to establish the
optimal temperature for TP-induced cardioprotection.
Methods
Heart perfusion and analysis of hemodynamic function
All procedures conformed to the UK Animals (Scientiﬁc
Procedures) Act 1986 and the Guide for the Care and Use
of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised
1996). Ethical approval was granted by the University of
Bristol, UK (Investigator number ub/09/012). Male Wistar
rats (250–260 g) were killed by stunning and cervical dislo-
cation. Hearts (0.75 g) were rapidly removed into ice-cold
Krebs–Henseleit buffer (KH) and Langendorff heart
perfusion was performed. Hemodynamic function was
measured throughout all the experiments using a latex
balloon in the left ventricle. Data acquisition and analysis
used a PowerLab System (ADInstruments, Bella Vista,
NSW, Australia). Hemodynamic left ventricular developed
pressure (LVDP) was calculated as the difference between
left ventricular systolic pressure (LVSP) and left ventricular
end-diastolic pressure (LVEDP), and work index (rate-
pressure product, RPP) as the product of LVDP and heart
rate (HR). Time derivatives of pressure were measured
during contraction (þdP/dt) and relaxation (2dP/dt).
During ischemia, the following parameters were measured:
time from the onset of ischemia to complete cessation of
contractility (time to zero LVDP), time from the onset of
ischemia to start of LVEDP increase due to ischemic contrac-
ture (time to ischemic contracture), and maximal LVEDP
increase during ischemic contracture (maximal contracture).
Experimental protocols
Experimental series 1 (Figure 1a)
After 44 min preischemia, global normothermic ischemia
was induced for 30 min by halting perfusion and immersing
the heart in KH at 378C. Normothermic perfusion (378C)
was then reinstated for 60 min. Hearts were divided into
ﬁve groups according to the preischemic protocol. Hearts of
the Control group (n ¼ 14) were not subjected to any
episode of hypothermic perfusion. TP hearts experienced
20-min equilibration at 378Ca n dt h r e ec y c l e so ft w om i n u t e s
hypothermic perfusion interspersed with six minutes nor-
mothermic perfusion. TP hearts were divided into four
groups according to the temperature of brief hypothermic per-
fusion: TP32 (n ¼ 8) – at 328C; TP26 (n ¼ 11) – at 268C; TP17
(n ¼ 10) – at 178Ca n dT P 7( n ¼ 9) – at 78C.
Experimental series 2 (Figure 1b)
After 36 min preischemia, hearts were cooled by perfusing
at 268C for one minute. This brief hypothermic perfusion
allows the myocardial temperature to equilibrate with the
hypothermic temperature of KH buffer.
1 Then the hearts
were subjected to global hypothermic ischemia for two
hours by halting perfusion and immersing the heart in per-
fusion buffer at 268C. Normothermic perfusion (378C) was
reinstated after the hypothermic ischemia and lasted for
two hours. Hearts were divided into two groups according
to the preischemic protocol. In hearts of the Control group
(n ¼ 11), normothermic perfusion was carried out for
36 min. In this series of experiments, hearts of the TP26
group (n ¼ 9) were subjected to two cycles of two minutes
hypothermic perfusion (268C) interspersed with six
minutes normothermic perfusion instead of three cycles
used in Experimental series 1. According to our preliminary
experiments (data not shown), three cycles may result in
LVEDP increase during reperfusion following hypothermic
ischemia. Meanwhile two cycles did not affect this par-
ameter (Figure 5a).
Experimental Series 3 (Figure 1c)
After 32 min preischemia, all hearts of this series were
arrested by four minutes normothermic perfusion with
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plegia). Hearts were then cooled by one-minute perfusion
with KH buffer containing 1 mmol/L procaine at 268C
and made globally ischemic for four hours at this tempera-
ture by halting perfusion and immersing the hearts in the
same buffer at 268C. Normothermic perfusion (378C) was
subsequently reinstated for two hours with no procaine
in the perfusion buffer. Hearts were divided into TP26
(n ¼ 7) and Isoproterenol/adenosine (n ¼ 5) groups accord-
ing to the preischemic protocol and compared with 6 and 5
control hearts respectively. The protocol of TP26 was similar
to that in Experimental Series 2, but after the second episode
of hypothermic perfusion, these hearts were perfused with
KH at 378C for two minutes prior to normothermic per-
fusion with procaine. Hearts of the Isoproterenol/adenosine
group were subjected to two minutes KH perfusion with
0.2 mmol/L isoproterenol followed by ﬁve minutes per-
fusion with 30 mmol/L adenosine prior to normothermic
perfusion with procaine.
Assays
Eight hearts of each of Control, TP26 and TP7 groups were
freeze-clamped at the end of the experimental protocol of
Series 1, ground under liquid nitrogen and stored at
2808C before the assays of cAMP and PKA.
cAMP
This was determined using a direct enzyme immunoassay
kit (Sigma, Poole, Dorset, UK). Samples of the frozen
hearts were suspended in 0.1 mol/L HCl at room tempera-
ture and centrifuged at 600g for 10 min. Protein concen-
tration in the supernatant was determined using a
bicinchoninic acid-based protein assay (Pierce, Thermo
Fisher Scientiﬁc, Cramlington, Northumberland, UK) and
adjusted to 3 mg/mL before the spectroﬂuorimetric assay
of cAMP according to the manufacturer’s instructions.
PKA activity
For the assay of PKA activity, samples of the frozen and
ground hearts were vortex-mixed into buffer (pH 7.4, 48C)
containing (mmol/L) 25 Tris-HCl, 0.5 EDTA, 0.5 EGTA, 10
b-mercaptoethanol (Sigma), and complete protease inhibi-
tor cocktail (Roche Diagnostics, Lewis, UK) and centrifuged
at 14,000g for ﬁve minutes. The protein concentration in the
supernatant was determined using the Biuret assay and
adjusted to 4 mg/mL. PKA activity was measured using
non-radioactive PepTag
w assays (Promega, Southampton,
Hampshire, UK) that rely on a change in charge of the
PepTag
w A1 peptide from þ1t o21 following phosphoryl-
ation. Samples (10 mgi n5mL) with PKA reaction mixture
(25 mL) were incubated at room temperature for 15 min.
After incubation, the samples were separated on a 0.8%
(w/v) agarose gel at 100 V for 15–20 min. Puriﬁed PKA cat-
alytic subunit was used as a positive control while the nega-
tive control contained only buffer. Bands were visualized
under ultraviolet light and quantiﬁed using an Alpha
Innotech ChemiImager 4400 with AlphaEase v5.5 software.
The ratio of ﬂuorescence intensity of phosphorylated and
non-phosphorylated peptide of each sample was used as a
measure of PKA activity.
Lactate dehydrogenase activity
Enzyme activity was determined in the efﬂuent perfusate
collected from the hearts of all groups prior to ischemia
and during each ﬁve minutes over the ﬁrst 15 min of
reperfusion as described earlier.
15
Infarct size
This was determined using triphenyltetrazolium chloride
(TTC) staining as described previously.
16 Necrotic and intact
areas of each side for each of six heart slices were determined
using AlphaEase v5.5 software and the total necrotic and
intact area of ventricular myocardium of each heart was calcu-
lated. Since the entire heart was at risk from global ischemia,
Figure 1 Outline of the protocols used in the experiments. (a) Experimental
series 1. C – control group, TP – temperature preconditioning. TP protocol
was performed at 32, 26, 17 or 78C. Thirty minutes global ischemia and
60 min reperfusion were carried out at normothermia (378C).
(b) Experimental series 2. TP26 – TP performed at 268C. Following the preis-
chemic protocol, all hearts were subjected to a one-minute preischemic 268C
perfusion prior to two hours global hypothermic ischemia at 268C.
Reperfusion was carried out at normothermia and lasted for two hours.
(c) Experimental series 3. TP26 – TP performed at 268C; Iso/Ade – two
minutes perfusion with 0.2 mmol/L isoproterenol followed by ﬁve minutes per-
fusion with 30 mmol/L adenosine. Polarized cardioplegia was induced by four
minutes perfusion with 1 mmol/L procaine at normothermia and one minute at
hypothermia (268C) following the preischemic protocol. Global hypothermic
ischemia (268C) with cardioplegia lasted for four hours Reperfusion at
normothermia without procaine lasted for two hours
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areas by the sum of total slice areas of the six slices to
obtain the percentage of necrosis. Infarct size was used as an
additional indicator of necrotic damage to myocardium in
hearts of the Experimental series 2 and 3 where the duration
of reperfusion was two hours. This duration of reperfusion
is sufﬁcient for identiﬁcation of infarct size using TTC and
has been used in a majority of studies on isolated rat heart.
Statistical analysis
Data are presented as means+SEM. Statistical signiﬁcances
of the differences between groups were evaluated using
two-way analysis of variance (ANOVA) followed by
Bonferroni post hoc test (hemodynamic function and LDH
release), one-way ANOVA followed by Turkey’s post hoc test
(cAMP concentration and PKA activity) or Student’s t-test
(infarct size) using Graphpad Prism v5.0 software. In
Series 3, data of TP26 and Isoproterenol/adenosine groups
were compared with different Control groups because the
experiments involving both TP26 and isoproterenol/adeno-
sine treatment were carried out separately. Differences were
considered signiﬁcant where P, 0.05.
Results
Experimental series 1 – temperature-dependence of TP
PKA activity and [cAMP] in hearts following the
different TP protocols
In this series of experiments, the cAMP concentration in TP26
hearts was signiﬁcantly increased while in TP7 it was similar
to controls (Figure 2a). Measurements of PKA activity
matched cAMP concentrations: a ratio of ﬂuorescence inten-
sity of phosphorylated to non-phosphorylated Pep Tag
w A1
peptide was increased in TP26 but not in TP7 hearts
(Figure 2b). Thus, TP26 hearts experienced signiﬁcant PKA
activation due to b-adrenergic stimulation, which was not
observed during brief hypothermic perfusion at 78C (TP7).
Hemodynamic function
The hemodynamic parameters of control hearts did not
change signiﬁcantly throughout 44 min preischemic per-
fusion. In all groups of TP hearts, hypothermic perfusion
during TP resulted in a considerable decrease of RPP,
mostly due to reduced HR. Diastolic pressure was elevated
during two minutes hypothermic perfusion. Subsequent
restoration of normothermia led to rapid augmentation of
contractile function, mainly as a result of increased LVDP.
However, some signiﬁcant differences between the TP
groups were apparent during preischemia (Figure 3). At
32 and 268C, the initial short-term increase of diastolic
pressure was followed by a fall to below the initial value.
At lower temperatures (17 and 78C), the initial increase in
diastolic pressure was much higher, but here a secondary
rise was observed during episodes of hypothermia. This
was greatest at 78C (Figures 3a and b). Figures 3c and d
compare the changes of RPP during periods of perfusion
at 32, 26, 17 and 78C. These data reveal that it was during
the second episode of normothermic perfusion that the
maximal increase of LVDP and RPP was greater in the
TP26 hearts than TP7 hearts.
In all groups of hearts, global normothermic ischemia
progressively reduced LVDP until complete cessation of
hemodynamic function was achieved, while diastolic
pressure increased later during ischemia, reﬂecting develop-
ment of ischemic contracture. However, TP26 hearts showed
the shortest time to zero LVDP, the longest delay before
ischemic contracture began and the lowest magnitude of
ischemic contracture similar to the changes of these par-
ameters reported previously.
1 Time to start of ischemic con-
tracture was also signiﬁcantly longer in TP17 than control
hearts (13.1+0.5 and 11.4+0.5 min respectively, P ,
0.05), while in TP32 and TP7 hearts these parameters were
not signiﬁcantly different from control hearts.
During reperfusion, recovery of hemodynamic function was
greatest in TP26 hearts with recovery of LVDP being twice as
high as for control hearts. TP32 and TP17 hearts did not show
any improvement in hemodynamic recovery while TP7 hearts
exhibited a further deterioration in function compared with
controls (Figures 4a–e). HR during reperfusion did not
differ from its preischemic value in any group of hearts.
Figure 2 Effects of TP at 26 and 78C on PKA activity and cAMP concen-
tration prior to ischemia. cAMP concentration and PKA activity were deter-
mined in hearts freeze-clamped and powdered under liquid nitrogen at the
end of the preischemic protocol of the experimental series 1 (Figure 1a).
(a) cAMP concentration was determined using a direct enzyme immunoassay
kit (Sigma). Control group of hearts; TP26 and TP7 – groups of hearts sub-
jected to temperature preconditioning protocol at 26 and 78C. (b) PKA activity
measured using the PepTag
w assay (Promega) and expressed as a ratio of ﬂu-
orescence intensity of phosphorylated to non-phosphorylated PepTag
w A1
peptide (P-A1 and A1, respectively). Inset: a representative gel containing
A1 and P-A1; NC – negative control, PC – positive control (PepTag
w A1
peptide phosphorylated by the PKA catalytic subunit), C – control group;
TP26 and TP7 – groups of hearts subjected to temperature preconditioning
protocol at 26 and 78C.  P , 0.05 versus Control. TP, temperature precondi-
tioning; PKA, protein kinase A; cAMP, cyclic AMP
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reperfusion largely depended on the recovery of LVDP.
Necrotic damage during reperfusion (LDH release)
This followed a similar pattern to the recovery of hemody-
namic function (Figure 4f) with the TP26 group showing a
considerably reduced LDH release whereas the TP7 group
showed increased LDH release compared with controls.
Experimental series 2 – cardioprotection by
TP during prolonged hypothermic ischemia
Hypothermic ischemia prolonged the time to zero LVDP
four-fold, increased time to onset of ischemic contracture
and reduced the amplitude of maximal contracture
two-fold compared with normothermic ischemia.
However, TP26 showed a shorter time from the onset of
hypothermic ischemia to zero LVDP (8.9+0.4 in TP26
group versus 13.7+0.9 min in the Control group, P ,
0.05) and 36% less ischemic contracture compared with
control (15.6+1.8 and 24.4+3.1 mmHg, respectively, P ,
0.05), consistent with these parameters measured during
normothermic ischemia.
Figure 3 Changes of preischemic LVEDP (a,b) and RPP (c,d) during three
cycles of hypothermic perfusion in TP hearts. LVEDP during hypothermia is
expressed in mmHg normalized for the value of prehypothermic LVEDP;
RPP is expressed as the percentage of the initial values measured at the
end of the prehypothermic (equilibration) period. Hypothermic perfusions in
TP26 and TP7 hearts (a and c) were performed at 26 and 78C while hypother-
mic perfusions in TP32 and TP17 hearts (b and d) were performed at 32 and
178C. LVEDP, left ventricular end-diastolic pressure; TP, temperature precon-
ditioning; RPP, rate-pressure product
Figure 4 Hemodynamic function recovery and LDH release during reperfusion
after 30 min global normothermic ischemia. Panels a–e present changes of
LVEDP, LVSP and LVDP (difference between LVSP and LVEDP) during 60 min
normothermic reperfusion after 30 min global normothermic ischemia in differ-
ent groups of hearts of the experimental series 1 (Figure 1a). (f) LDH activity
measured in the efﬂuent perfusate during the ﬁrst 15 min reperfusion in
the groups of hearts of the experimental series 1.  P, 0.05 versus Control;
#P, 0.05 versus TP26. There was no difference in heart rate recovery
between the groups and the symbol † indicates statistically signiﬁcant differ-
ences (P, 0.05) in both LVDP and RPP versus Control. LVEDP, left ventricular
end-diastolic pressure; LVSP, left ventricular systolic pressure; LVDP, left ventri-
cular developed pressure; LDH, lactate dehydrogenase; RPP, rate-pressure
product
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improved recovery of hemodynamic function (Figure 5a)
and LDH release appeared to be ﬁve-fold lower than
control at 10-min of reperfusion (Figure 5b). LDH release
paralleled the infarct size measurements (Figure 5c): necro-
tic areas in control and TP26 hearts were 64.3+2.3%
and 39.5+2.2 5% of the whole heart area, respectively
(P , 0.001).
Experimental series 3 – cardioprotection by TP or
isoproterenol/adenosine treatment during prolonged
hypothermic ischemia with polarized cardioplegia
Prior to ischemia, perfusion with 1 mmol/L procaine caused
heart contraction to stop after 2.3+0.2, 2.2+0.2 and 2.4+
0.3 min in control, TP26 and isoproterenol/adenosine
hearts, respectively (P . 0.05). Hearts not treated with pro-
caine were unable to recover after four hours hypothermic
ischemia (268C) (data not shown) while procaine prevented
any contracture during four hours hypothermic ischemia
and enabled hearts to recover partially during reperfusion.
However, both TP26 and isoproterenol/adenosine treat-
ments were still able to improve hemodynamic function
recovery and reduce LDH release during reperfusion in
hearts arrested with hypothermic cardioplegia (Figures 6a,
b and 7a, b). The data of Figures 6c and 7c show that
infarct size was also signiﬁcantly less in isoproterenol/ade-
nosine hearts compared with controls (43.2+4.3% versus
72.8+2.0% of the whole heart area, P , 0.01) as it was for
TP26 hearts (35.7+2.7% versus 56.0+5.3% of the whole
heart area, P , 0.01).
Discussion
TP is optimal at 268 8 8 8 8C
The data presented here demonstrate that the protective
effects of TP are critically dependent on the temperature
of the short-term episodes of hypothermic perfusion, with
268C giving the best protection. During global normother-
mic ischemia, hearts of the TP26 group showed the shortest
time to zero LVDP, the longest time to start of ischemic con-
tracture and the lowest increase of diastolic pressure during
ischemic contracture. We have previously shown that these
effects reﬂect better preservation of high-energy phosphates
in the TP26 hearts.
1 These hearts also had the highest hemo-
dynamic function recovery and the lowest LDH release
during reperfusion (Figure 4) indicating the lowest necrotic
Figure 5 Hemodynamic function recovery, LDH release and infarct size after two hours global hypothermic ischemia and two hours reperfusion. (a) Changes of
LVEDP, LVSP and LVDP (difference between LVSP and LVEDP) during two hours normothermic reperfusion after two hours global hypothermic ischemia (268C) in
the groups of hearts of the experimental series 2 (Figure 1b). (b) LDH activity measured in the efﬂuent perfusate during the ﬁrst 15 min reperfusion in the groups of
hearts of the experimental series 2. (c) Infarct size measured at the end of two hours normothermic reperfusion in the groups of hearts of the experimental
series 2. Infarct size is expressed as mean+SEM of the percentage of necrotic area relatively to the whole heart area. TP26 – group of hearts subjected to temp-
erature preconditioning protocol at 268C. Inset: corresponding representative images of the heart slices.  P , 0.05 versus Control. There was no difference in
heart rate recovery between the groups and the symbol † indicates statistically signiﬁcant differences (P , 0.05) in both LVDP and RPP versus Control.
LVEDP, left ventricular end-diastolic pressure; LVSP, left ventricular systolic pressure; LVDP, left ventricular developed pressure; LDH, lactate dehydrogenase;
RPP, rate-pressure product
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higher (328C) temperatures was not as protective, while
the use of 78C actually exacerbated reperfusion injury and
was associated with lower hemodynamic recovery and
higher LDH release than in the control hearts.
One reason for the deleterious effect of TP at 78Cm a yb e
an excessive accumulation of calcium in the myocardium
as a result of an imbalance between active and passive
ion membrane transport.
2,17 During hypothermia,
ATP-dependent ion channels become inhibited while Na
þ,
Ca
2þ and K
þ diffusion are less affected. An imbalance
between the activity of the ATP-dependent Ca
2þ pump of
sarcoplasmic reticulum and the ryanodine receptors may
also contribute to intracellular Ca
2þ accumulation during
hypothermia as may the activity of the Na
þ/Ca
2þ exchan-
ger. The severity of this imbalance depends on temperature.
Thus, it has been shown that moderate hypothermia
reduces membrane-bound Ca
2þ-pump activity while
severe hypothermic storage abolishes it.
18,19 Stowe et al.
showed that at 278C, paced hearts adapt functionally to
the greater accumulation of Ca
2þ during diastole by redu-
cing the rate of release of Ca
2þ. However, at 178C, despite
the very prolonged release and re-uptake of Ca
2þ over the
cardiac cycle, diastolic Ca
2þ loading becomes so marked
that relaxation is impaired, and contractility decreases.
2
The dependence of the LVEDP on the temperature of the
hypothermic episodes during TP (Figure 3) is consistent
with this. Thus, the lowest LVEDP was found in TP32
hearts while the highest value of this parameter was in
TP7 hearts (Figures 3a and b). The increased diastolic
pressure can be explained, at least partially, by a higher
accumulation of intracellular Ca
2þ at greater hypothermia.
This hypothesis can be supported by the observation that
rapid cooling of the myocardium to 18C causes contracture
as a result of calcium release from sarcoplasmic reticulum.
20
It seems likely that at 78C, Ca
2þ accumulation is substan-
tially greater than at 26 and 178C and contributes to the
greater ischemia/reperfusion damage.
21 However, moderate
intracellular calcium accumulation before prolonged ische-
mia has been reported to be protective
22,23 and may play a
role in the cardioprotective effects of TP, which our data
suggest is optimal at 268C.
The considerable rise of LVDP and RPP during
re-warming (Figures 3c and d) may also be partially
Figure 6 Hemodynamic function recovery, LDH release and infarct size after four hours global hypothermic ischemia and polarized cardioplegia and two hours
reperfusion in TP26 hearts. (a) Changes of LVEDP, LVSP and LVDP (difference between LVSP and LVEDP) during two hours normothermic reperfusion after four
hours global hypothermic ischemia (268C) and polarized cardioplegia, induced by 1 mmol/L procaine, in the Control and TP26 groups of hearts of the experimen-
tal series 3 (Figure 1c). (b) LDH activity measured in the efﬂuent perfusate during the ﬁrst 15 min reperfusion in the Control and TP26 groups of hearts of the
experimental series 3. (c) Infarct size measured at the end of two hours normothermic reperfusion in the Control and TP26 groups of hearts of the experimental
series 3. Infarct size is expressed as mean+SEM of the percentage of necrotic area relatively to the whole heart area. Inset: corresponding representative images
of the heart slices.  P , 0.05 versus Control. There was no difference in heart rate recovery between the groups and the symbol † indicates statistically signiﬁcant
differences (P , 0.05) in both LVDP and RPP versus Control. LVEDP, left ventricular end-diastolic pressure; LVSP, left ventricular systolic pressure; LVDP, left ven-
tricular developed pressure; LDH, lactate dehydrogenase; RPP, rate-pressure product
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2þ accumulation in cardiomyocytes during
hypothermia. However, it may also involve PKA activation
by the release of endogenous catecholamines during
h y p o t h e r m i a ,w h i c hi nt u r nm a ym o d u l a t eC a
2þ homeostasis.
Indeed, TP at 268C (TP26) signiﬁcantly increased cAMP con-
centration and PKA activity leading to cardioprotection
during ischemia and reperfusion (see
3 and Figures 2a
and b). Interestingly, we found no difference in these par-
ameters in TP7 hearts compared with controls (Figures 2a
and b). This ﬁnding is consistent with a higher RPP elevation
in TP26 hearts compared with TP7 hearts after the second
short-term episode of hypothermic perfusion (Figure 3c). It
would appear that severe and/or prolonged hypothermia, if
not supported by other protective measures, switches off the
mechanism(s) responsible for the myocardial response to
b-adrenergic stimulation. This would affect the ability of the
heart to regain its contractility during re-warming and also
disrupt the signal transduction pathways of TP, thus explain-
ing why TP7 hearts experienced greater ischemia/reperfusion
damage than control hearts. By contrast, short-term episodes
of hypothermic perfusion at 268C stimulate this
b-adrenergic response, enabling hearts to survive better
during prolonged ischemia.
3
TP protects hearts against prolonged hypothermic
ischemia
A number of studies have demonstrated the ability of IP to
protect the heart against prolonged hypothermic ischemia,
which may occur during cardiac surgery and heart trans-
plantation.
24,25 In these experiments, mild to moderate
hypothermia (32–178C) was employed. However, others
have shown no protection when IP hearts were stored at
lower temperature (6–88C).
26 Thus, the ability of IP to con-
tribute to cardioprotection during hypothermic ischemia is
temperature dependent. There are some similarities in the
signaling mechanisms of IP and TP,
1,3 suggesting that TP
might confer additional protection to hypothermic preser-
vation of hearts as does IP. The nature of the TP protocol
might make it more effective than IP in providing such
Figure 7 Hemodynamic function recovery, LDH release and infarct size after four hours global hypothermic ischemia and polarized cardioplegia and two hours
reperfusion in hearts treated consecutively with isoproterenol and adenosine (Iso/Ade group). (a) Changes of LVEDP, LVSP and LVDP (difference between LVSP
and LVEDP) during two hours normothermic reperfusion after four hours global hypothermic ischemia (268C) and polarized cardioplegia, induced by 1 mmol/L
procaine, in Control and Iso/Ade groups of hearts of the experimental series 3 (Figure 1c). (b) LDH activity measured in the efﬂuent perfusate during the ﬁrst
15 min reperfusion in the Control and Iso/Ade groups of hearts of the experimental series 3. (c) Infarct size measured at the end of two hours normothermic reper-
fusion in the Control and Iso/Ade groups of hearts of the experimental series 3. Infarct size is expressed as mean+SEM of the percentage of necrotic area rela-
tively to the whole heart area. Inset: corresponding representative images of the heart slices. P, 0.05 versus Control. There was no difference in heart rate recovery
between the groups and the symbol † indicates statistically signiﬁcant differences (P, 0.05) in both LVDP and RPP versus Control. LVEDP, left ventricular end-
diastolic pressure; LVSP, left ventricular systolic pressure; LVDP, left ventricular developed pressure; LDH, lactate dehydrogenase; RPP, rate-pressure product
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hearts showed signiﬁcantly improved hemodynamic func-
tion recovery, and dramatically reduced LDH release and
infarct size after two hours ischemia at 268C (Figure 5).
Hypothermia reduced both the speed of decline of LVSP
during ischemia and the extent of ischemic contracture.
Yet even under these conditions, TP26 was still able to
shorten the time to zero LVDP and reduce ischemic contrac-
ture. As the key cause of ischemic contracture is lack of
MgATP,
27 it is possible that the TP26 protocol enhances
ATP preservation during ischemia at 268C over and above
the energy sparing effect of hypothermia,
28 just as we
observed during normothermic ischemia.
1 Depletion of
ATP during ischemia together with oxidative stress during
reperfusion promotes opening of the MPTP that ultimately
causes irreversible damage to myocardium.
29 We have
recently shown that TP26 strongly inhibits MPTP opening
during reperfusion
1,3 and this might be explained, at least
partially, by its ability to preserve myocardial ATP levels.
TP enhances cardioprotection by hypothermic
polarized cardioplegia
Cardioplegic arrest using a hyperkalemic extracellular sol-
ution remains the current gold standard for cardioprotection
during cardiac surgery.
10,11 Hyperkalemia induces arrest by
establishing a new resting membrane potential which is at a
more positive value (i.e. is depolarized from normal) and is,
therefore, termed ‘depolarized’ arrest. However, it has been
shown that the Na
þ ‘window’ current during depolarized
cardioplegia would lead to increased intracellular [Ca
2þ]
through the calcium ‘window’ current.
30 High [Ca
2þ]i may
also be caused by calcium inﬂux through the slow calcium
channel and reversed activity of the Na
þ/Ca
2þ exchanger.
11
This would lead to contracture, calcium overload and sub-
sequent myocardial injury, particularly during reperfusion.
A potential way to address this problem would be to
induce a polarized arrest at membrane potentials closer to
the normal ‘resting’ membrane potential. Agents with
local anesthetic effects (such as procaine and lidocaine) are
available clinically and have been widely used either alone
or in combination with other agents to induce cardiac
arrest.
31 Their beneﬁcial effects include reduction of ionic
imbalance leading to reduced energy utilization, and
hence improved protection from a cellular perspective.
10
However, the protective effect of polarized cardioplegia is
also time-limited. Thus in our experiments, hemodynamic
recovery of control hearts, arrested prior to four hours
global hypothermic ischemia (268C) with 1 mmol/Lp r o -
caine, was very poor. These data conﬁrm the observation
that cardiac surgery continues to be limited by an inability
to achieve complete myocardial protection from ischemia–
reperfusion injury despite the use of hypothermia and car-
dioplegic arrest.
32 Furthermore, a number of studies indicate
very restricted
24 or no ability of IP to improve heart recovery
after cardioplegic arrest.
33 However, TP26 was able to
improve hemodynamic function recovery and signiﬁcantly
reduce necrotic damage under these conditions (Figure 6).
Therefore, a pharmacological treatment based on the mech-
anisms of TP could be beneﬁcial when using polarized
cardioplegia for hypothermic heart preservation during
cardiac surgery and transplantation. We have recently
shown that the key mechanism of TP is the consecutive
PKA and PKC activation. We induced activation of these
kinases pharmacologically, using a non-selective
b-adrenergic agonist isoproterenol and a PKC activator ade-
nosine. This consecutive isoproterenol/adenosine treatment
protected the isolated rat heart against normothermic global
ischemia very effectively.
3 Here we demonstrate that such
consecutive treatment can also protect the heart against pro-
longed ischemia during hypothermia and polarized cardio-
plegic arrest just as effectively as TP. Because
pharmacological treatment is easier to perform than short-
term episodes of hypothermia during cardiac surgery, this
treatment may provide an intervention that will help to
protect hearts in these conditions yet has much greater clini-
cal potential than TP.
In conclusion, the novelty of our study is as follows:
(1) Choice of the hypothermic temperature is critical to the
cardioprotective effects of TP; 268C is optimal for the TP
protocol while temperatures below 178C afford no cardi-
oprotection and can be detrimental. This fact may be
taken into consideration when choosing the level of
hypothermia during surgery;
(2) Pharmacological signaling associated with b-adrenergic
stimulation during TP and cardioprotection is tempera-
ture dependent;
(3) TP at 268C confers additional protection to hypothermic
ischemia and to hypothermic polarized cardioplegia, in
contrast to IP, which affords little additional protection
to cardioplegic arrest;
(4) Pharmacological mimics of TP (isoproterenol/adenosine
treatment) prior to hypothermic ischemic cardioplegic
arrest may provide clinical beneﬁt during heart
surgery and transplantation.
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